Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol

PHASE3UnknownINTERVENTIONAL
Enrollment

433

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2020

Conditions
Cervical Intraepithelial Neoplasia
Interventions
DRUG

Imiquimod

12,5 mg imiquimod three times per week during 16 weeks

PROCEDURE

LLETZ

surgical treatment for CIN, current gold standard

Trial Locations (1)

3015 CE

RECRUITING

Erasmus Medical center, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Maastricht University Medical Center

OTHER

collaborator

Meander Medisch Centrum

OTHER

collaborator

Albert Schweitzer Hospital

OTHER

collaborator

Sint Franciscus Gasthuis

OTHER

collaborator

Catharina Ziekenhuis Eindhoven

OTHER

lead

Erasmus Medical Center

OTHER